ArticleInternational journal of molecular sciences2016
Molecular Neurobiology and Promising New Treatment in Depression.
Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- TM5441, a PAI-1 inhibitor, attenuates chronic stress-induced anxio-depressive-like behaviors by restoring the hippocampal PAI-1/tPA/BDNF axis.Psychopharmacology · 2026Article
- The HPA axis and kynurenine pathway: exploring the role of stress and neuroinflammation in treatment-resistant depression.Pharmacological reports : PR · 2026Review
- Editorial of Special Issue "Latest Multifactorial Developments on Neuropsychiatric Disorders and Manifestations".Current issues in molecular biology · 2025Article
- Treatment-resistant depression: molecular mechanisms and management.Molecular biomedicine · 2024Review
- Article
- Therapeutic potential and possible mechanisms of ginseng for depression associated with COVID-19.Inflammopharmacology · 2024Review
- The Associations of Vitamin D with Ovarian Reserve Markers and Depression: A Narrative Literature Review.Nutrients · 2023Review
- Phenolic Acids as Antidepressant Agents.Nutrients · 2022Review
- Integrative PheWAS analysis in risk categorization of major depressive disorder and identifying their associations with genetic variants using a latent topic model approach.Translational psychiatry · 2022Article
- Neuroanatomical, Biochemical, and Functional Modifications in Brain Induced by Treatment with Antidepressants.Molecular neurobiology · 2022Review
- Baicalein Exerts Therapeutic Effects against Endotoxin-Induced Depression-like Behavior in Mice by Decreasing Inflammatory Cytokines and Increasing Brain-Derived Neurotrophic Factor Levels.Antioxidants (Basel, Switzerland) · 2022Article
- Article
- Ghrelin mediated regulation of neurosynaptic transmitters in depressive disorders.Current research in pharmacology and drug discovery · 2022Review
- Prevention of Stress-Induced Depressive-like Behavior by Saffron Extract Is Associated with Modulation of Kynurenine Pathway and Monoamine Neurotransmission.Pharmaceutics · 2021Article
- Nutritional therapy can reduce the burden of depression management in low income countries: A review.IBRO neuroscience reports · 2021Review
- The miRNome of Depression.International journal of molecular sciences · 2021Review
- A Load to Find Clinically Useful Biomarkers for Depression.Advances in experimental medicine and biology · 2021Article
- Changes in Cortisol but Not in Brain-Derived Neurotrophic Factor Modulate the Association Between Sleep Disturbances and Major Depression.Frontiers in behavioral neuroscience · 2020Article
- The Role of BDNF on Neural Plasticity in Depression.Frontiers in cellular neuroscience · 2020Article
- Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines.Advances in pharmacological sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The limited effects of currently available antidepressants are becoming an urgent issue in depression research. It takes a long time to determine treatment effects, and the overall remission rate is low. Although we expect the development of non-monoamine antidepressants in the near future, efforts in this regard over the past several decades have not yet been compensated. Thus, researchers and clinicians should clarify the neurobiological mechanisms of integrated modulators that regulate changes in genes, cells, the brain, and behaviors associated with depression. In this study, we review molecular neurobiological theories and new treatments for depression. Beyond neuroanatomy and monoamine theory, we discuss cells and molecules, neural plasticity, neurotrophisms, endocrine mechanisms, immunological mechanisms, genetics, circadian rhythms, and metabolic regulation in depression. In addition, we introduce the possibility of new antidepressant drug development using protein translation signaling (mTOR) pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.